{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:10Z","timestamp":1793320570301,"version":"4.5.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, precision medicine for non-small cell lung cancer (NSCLC) has made significant strides, particularly with advancements in diagnostic and therapeutic technologies. Targeted 7therapies and Anti-PD-(L)1 Therapies have emerged as vital treatment options, yet KRAS mutations, especially KRAS G12C, have been historically difficult to address. Due to the unique activation mechanism of KRAS G12C has led to the development of specific inhibitors, such as AMG 510 and MRTX849, which show promising therapeutic potential. However, results from the CodeBreaK 200 Phase III trial indicated that AMG 510 did not significantly improve overall survival compared to docetaxel. Resistance after prolonged use of KRAS G12C inhibitors continues to pose a challenge, prompting interest in new drugs and combination strategies. KRAS mutations can impair tumor-infiltrating T cell function and create an immunosuppressive tumor microenvironment, making the combination of KRAS G12C inhibitors with anti-PD-(L)1 therapies particularly appealing. Preliminary data suggest these combinations may enhance both survival and quality of life, though safety concerns remain a barrier. Ongoing research is crucial to refine treatment regimens and identify suitable patient populations. This review focuses on the development of KRAS G12C inhibitors in monotherapy and combination therapies for NSCLC, discussing major clinical trials and future research directions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1509173","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:21:44Z","timestamp":1744680104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211066064","article-title":"KRAS and MET in non-small-cell lung cancer: Two of the new kids on the \u2018drivers\u2019 block","volume":"16","author":"Garcia-Robledo","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.0454","article-title":"KRAS mutation: Should we test for it, and does it matter","volume":"31","author":"Roberts","year":"2013","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.09.004","article-title":"Differential expression of biomarkers in men and women","volume":"36","author":"Planchard","year":"2009","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants","volume":"277","author":"Scheffzek","year":"1997","journal-title":"Sci (New York NY)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: From biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Ca"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-ct246","article-title":"Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and safety of KRASG12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: Results from a phase 2 pivotal study","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"468214","DOI":"10.1200\/jco.2024.42.36_suppl.468214","article-title":"A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation","volume":"42","author":"Shi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"108050","DOI":"10.1016\/j.pharmthera.2021.108050","article-title":"Resistance looms for KRAS G12C inhibitors and rational tackling strategies","volume":"229","author":"Zhang","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: Function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 codeBreaK 100\/101: First report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.066","article-title":"LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na\u00efve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"34","author":"Garassino","year":"2023","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.jtocrr.2020.100052","article-title":"Outcomes of patients with advanced NSCLC from the intergroupe francophone de canc\u00e9rologie thoracique biomarkers France study by KRAS mutation subtypes","volume":"1","author":"Ruppert","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: Split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2012.09.007","article-title":"KRAS mutations in lung cancer","volume":"14","author":"Karachaliou","year":"2013","journal-title":"Clin Lung Ca"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.cd-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11307-021-01689-8","article-title":"RAS-driven macropinocytosis of albumin or dextran reveals mutation-specific target engagement of RAS p.G12C inhibitor ARS-1620 by NIR-fluorescence imaging","volume":"24","author":"Sutton","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c05203","article-title":"Fluorescent biosensor for measuring ras activity in living cells","volume":"144","author":"Weeks","year":"2022","journal-title":"J Am Chem Soc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7999","article-title":"Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer","volume":"11","author":"Molina-Arcas","year":"2019","journal-title":"Sci Trans Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J Med Chem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1158\/1538-7445.AM2019-3090","article-title":"Abstract 3090:In vivocharacterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models","volume":"79","author":"Rex","year":"2019","journal-title":"Cancer Research"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of codeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/jco.2024.42.16_suppl.8512","article-title":"Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"P05","DOI":"10.1158\/1535-7163.targ-21-p05-01","article-title":"Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors","volume":"20","author":"Ramalingam","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"P05","DOI":"10.1158\/1535-7163.targ-21-p05-02","article-title":"Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)","volume":"20","author":"Gandara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2022-ct204","article-title":"Abstract CT204: A phase 1\/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)","volume":"82","author":"Govindan","year":"2022","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J med. Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/ijms24010669","article-title":"Drug repurposing against KRAS mutant G12C: A machine learning, molecular docking, and molecular dynamics study","volume":"24","author":"Srisongkram","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"Jaenne","year":"2022","journal-title":"New Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jtho.2023.09.152","article-title":"MA06.04 KRYSTAL-1: Two-year follow-up of adagrasib (MRTX849) monotherapy in patients with advanced\/metastatic KRASG12C-mutated NSCLC","volume":"18","author":"Gadgeel","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.tps9129","article-title":"KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation","volume":"39","author":"Mok","year":"2021","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: Preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS(G12C)-mutated non-small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and discovery of MRTX0902, a potent, selective, brain- penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J Med Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15829","article-title":"D-1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity","volume":"114","author":"Shi","year":"2023","journal-title":"Cancer Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1158\/1538-7445.am2021-1056","article-title":"Abstract 1056: Potent in vivo anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor models with KRas G12C mutation","volume":"81","author":"Shi","year":"2021","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/1538-7445.am2021-932","article-title":"Abstract 932: Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models","volume":"81","author":"Shi","year":"2021","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: Phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.1200\/jco.2024.42.16_suppl.8605","article-title":"Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib\/II study","volume":"42","author":"Song","year":"2024","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct030","article-title":"Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study","volume":"83","author":"Zhou","year":"2023","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"S1512","DOI":"10.1016\/j.annonc.2023.10.241","article-title":"106P Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies","volume":"34","author":"Yuan","year":"2023","journal-title":"Ann Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S1662","DOI":"10.1016\/j.annonc.2023.10.584","article-title":"LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.17_suppl.lba8511","article-title":"KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","volume":"42","author":"Gregorc","year":"2024","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.040","article-title":"Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models","volume":"33","author":"Wang","year":"2022","journal-title":"Ann Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/jco.2022.40.16_suppl.3089","article-title":"A phase I\/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B69","unstructured":"Pharma\n              J\n            \n          \n          \n          2024"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01438","article-title":"JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS(G12C) for the treatment of solid tumors","volume":"65","author":"Lorthiois","year":"2022","journal-title":"J Med Chem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1158\/1538-7445.am2022-4026","article-title":"Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4\/6","volume":"82","author":"Weiss","year":"2022","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.targ-21-p124","article-title":"Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models","volume":"20","author":"Brachmann","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.053","article-title":"KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","volume":"118","author":"Cassier","year":"2024","journal-title":"Int J Radiat OncologyBiologyPhys"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.072","article-title":"A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression \u22651% and an STK11 co-mutation","volume":"118","author":"Lindsay","year":"2024","journal-title":"Int J Radiat OncologyBiologyPhys"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps9144","article-title":"KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC","volume":"41","author":"Cappuzzo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.151","article-title":"MA06.03 kontRASt-01: Preliminary safety and efficacy of JDQ443 + TNO155 in patients with advanced, KRAS G12C-mutated solid tumors","volume":"18","author":"Negrao","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"116720","DOI":"10.1016\/j.biopha.2024.116720","article-title":"ABCB1 attenuates brain exposure to the KRAS(G12C) inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure","volume":"175","author":"Rijmers","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1158\/1538-7445.am2021-1259","article-title":"Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor","volume":"81","author":"Peng","year":"2021","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct028","article-title":"Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors","volume":"83","author":"Murciano-Goroff","year":"2023","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/jco.2024.42.3_suppl.94","article-title":"Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study","volume":"42","author":"Hollebecque","year":"2024","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/jco.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c09917","article-title":"Atroposelective negishi coupling optimization guided by multivariate linear regression analysis: Asymmetric synthesis of KRAS G12C covalent inhibitor GDC-6036","volume":"144","author":"Xu","year":"2022","journal-title":"J Am Chem Soc"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.2c04417","article-title":"Quantifying KRAS G12C covalent drug inhibitor activity in mouse tumors using mass spectrometry","volume":"95","author":"Tran","year":"2023","journal-title":"Anal Chem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.023","article-title":"OA03.04 phase I A study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation","volume":"17","author":"Sacher","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J Med Chem"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1538-7445.am2021-1271","article-title":"Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor","volume":"81","author":"Savarese","year":"2021","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"S468","DOI":"10.1016\/j.annonc.2023.09.1851","article-title":"665P First-in-human, phase Ia\/b, dose-escalation\/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation","volume":"34","author":"Heymach","year":"2023","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1158\/1538-7445.am2022-2667","article-title":"Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation","volume":"82","author":"Waizenegger","year":"2022","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-ct119","article-title":"Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","volume":"84","author":"Dong","year":"2024","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.esmoop.2024.102273","article-title":"44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC","volume":"9","author":"Rojas","year":"2024","journal-title":"ESMO Open"},{"key":"B93","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/oncolo\/oyab080","article-title":"Phase I study of JNJ-74699157 in patients with advanced solid tumors harboring the KRAS G12C mutation","volume":"27","author":"Wang","year":"2022","journal-title":"Oncologist"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01436-y","article-title":"Resistance to KRAS G12C inhibition in non-small cell lung cancer","volume":"25","author":"Di Federico","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: Insights from in vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: Critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","first-page":"189108","DOI":"10.1016\/j.bbcan.2024.189108","article-title":"Activity and resistance to KRAS(G12C) inhibitors in non-small cell lung cancer and colorectal cancer","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochim Biophys Acta Rev Ca"},{"key":"B100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: Resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Ca"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0856","article-title":"KRAS inhibitor resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"B103","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"B107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Ca"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","article-title":"Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis","volume":"18","author":"Guo","year":"2020","journal-title":"J Trans Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12609","article-title":"Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma","volume":"44","author":"Jiang","year":"2024","journal-title":"Cancer Commun (London England)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202182","article-title":"KRAS mutations are negatively correlated with immunity in colon cancer","volume":"13","author":"Fu","year":"2020","journal-title":"Aging"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0241","article-title":"Mutant KRAS conversion of conventional T cells into regulatory T cells","volume":"4","author":"Zdanov","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1159\/000067596","article-title":"The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells","volume":"129","author":"Levings","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26124","article-title":"Complex formation between platelet-derived growth factor receptor \u03b2 and transforming growth factor \u03b2 receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts","volume":"9","author":"Aoto","year":"2018","journal-title":"Oncotarget"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.10","article-title":"Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS","volume":"1","author":"Ward","year":"2020","journal-title":"MedComm"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (London England)"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-13-0646","article-title":"Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit","volume":"4","author":"Zhu","year":"2014","journal-title":"Cancer Discov"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-2840","article-title":"IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer","volume":"76","author":"Caetano","year":"2016","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/jci153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0620","article-title":"Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Muthalagu","year":"2020","journal-title":"Cancer Discov"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402913121","article-title":"Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors","volume":"121","author":"Fern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B123","doi-asserted-by":"publisher","first-page":"101006","DOI":"10.1016\/j.xcrm.2023.101006","article-title":"MYC activation impairs cell-intrinsic IFN\u03b3 signaling and confers resistance to anti-PD1\/PD-L1 therapy in lung cancer","volume":"4","author":"Alburquerque-Bejar","year":"2023","journal-title":"Cell Rep Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"B126","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.immuni.2018.09.020","article-title":"The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment","volume":"49","author":"Mollaoglu","year":"2018","journal-title":"Immunity"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-2627","article-title":"CRISPR-cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer","volume":"84","author":"Boumelha","year":"2024","journal-title":"Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int"},{"key":"B130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41698-024-00626-6","article-title":"Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome","volume":"8","author":"Zhao","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer discov"},{"key":"B132","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-023-00471-6","article-title":"Targeting focal adhesion kinase boosts immune response in KRAS\/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment","volume":"13","author":"Qiao","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.cd-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"B134","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.can-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00208-6","article-title":"ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer","volume":"2","author":"Deng","year":"2021","journal-title":"Nat ca"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774103","article-title":"mTOR-mediated regulation of immune responses in cancer and tumor microenvironment","volume":"12","author":"Mafi","year":"2021","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2021.12.005","article-title":"EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion","volume":"185","author":"Marzio","year":"2022","journal-title":"Cell"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/j.gastro.2021.12.273","article-title":"Loss of rnf43 accelerates kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma","volume":"162","author":"Hosein","year":"2022","journal-title":"Gastroenterology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00375-9","article-title":"Metabolic networks in mutant KRAS-driven tumours: Tissue specificities and the microenvironment","volume":"21","author":"Kerk","year":"2021","journal-title":"Nat Rev Ca"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203757","article-title":"Mutant KRAS drives immune evasion by sensitizing cytotoxic T-cells to activation-induced cell death in colorectal cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0297","article-title":"Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0462","article-title":"The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B145","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1038\/s41467-021-26214-x","article-title":"Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry","volume":"12","author":"van Maldegem","year":"2021","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci Adv"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1172\/jci155523","article-title":"Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition","volume":"132","author":"Tsai","year":"2022","journal-title":"J Clin Invest"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0111","article-title":"Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration","volume":"12","author":"Knab","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: Pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz453.002","article-title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev pathol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl6464","article-title":"Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses","volume":"10","author":"Cole","year":"2024","journal-title":"Sci Adv"},{"key":"B153","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/jco.2024.42.16_suppl.8510","article-title":"Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Burns","year":"2024","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps8651","article-title":"Krascendo-170 Lung: A phase Ib\/II study of divarasib + pembrolizumab \u00b1 platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Skoulidis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.jtocrr.2021.100213","article-title":"Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: Case report","volume":"2","author":"Begum","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00030","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.ctarc.2023.100743","article-title":"Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report","volume":"36","author":"Desai","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief report: Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (Ligand)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.cd-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat Commun"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"B163","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41401-023-01194-4","article-title":"From bench to bedside: Current development and emerging trend of KRAS-targeted therapy","volume":"45","author":"Chen","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B164","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/jco.2024.42.16_suppl.3008","article-title":"Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz453.002","article-title":"LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"116058","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1509173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:21:46Z","timestamp":1744680106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1509173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2025.1509173"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1509173","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1509173"}}